Daily BriefsSouth Korea

Daily Brief South Korea: Cosmochemical, Hanmi Science, Hanmi Pharm and more

In today’s briefing:

  • Market Talk on the Five Stocks Hitting the Lower Limit Yesterday
  • A Pair Trade Between Hanmi Science and Hanmi Pharm
  • ESG Report: Hanmi Pharmaceutical Co. (128940 KS) And Hanmi Science (008930 KS)


Market Talk on the Five Stocks Hitting the Lower Limit Yesterday

By Sanghyun Park

  • The trigger for yesterday’s sell-off was the sudden collective decision of the brokerages that had been allowing credit trading for these stocks to halt credit trading simultaneously.
  • There is a possibility that the identities of the stocks under investigation were leaked, and these brokerages took preemptive actions.
  • There have also been observations of large-cap stocks that may become the next targets. Some notable examples include Cosmo Chemical, Kum Yang, Posco International, and Ecopro Co.

A Pair Trade Between Hanmi Science and Hanmi Pharm

By Douglas Kim

  • There has been a big divergence in the share prices of Hanmi Science and Hanmi Pharm in the past two months. 
  • This divergence in share price appears to be a bit too excessive and we believe this gap is likely to narrow in the coming weeks.  
  • We like a pair trade between going long Hanmi Science and going short on Hanmi Pharm. 

ESG Report: Hanmi Pharmaceutical Co. (128940 KS) And Hanmi Science (008930 KS)

By Heejeong (Hollie) Park

  • Hanmi Pharmaceutical and Hanmi Science have demonstrated consistent financial performance through aggressive R&D investments, with significant achievements based on internally developed products in 2022.
  • The new leadership structure of the company has the potential to improve corporate governance transparency, but there is a need for further shareholder-friendly changes, such as expanding dividend policies.
  • Overall, the company’s current status, valuation, and ESG performance trends indicate positive prospects, including transparent management practices, sustained investment in R&D, and plans to enhance dividend policies.

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars